Ad-TD-nsIL12(Ad-TD-nsIL12) - 药物靶点：IL-12_在研适应症：弥漫内生性脑桥神经胶质瘤，结直肠癌，卵巢癌_专利_临床

概要

基本信息

药物类型

溶瘤病毒

别名-

靶点

IL-12

作用机制

IL-12调节剂(白细胞介素-12复合体调节剂)

治疗领域

肿瘤神经系统疾病其他疾病+ [3]

在研适应症

弥漫内生性脑桥神经胶质瘤结直肠癌卵巢癌+ [2]

非在研适应症-

原研机构-

在研机构

郑州大学

首都医科大学

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 9145

Sequence Code 138947linker

Sequence Code 13225263

Sequence Code 13225258

关联

4

项与 Ad-TD-nsIL12 相关的临床试验

ChiCTR2300073240 / Recruiting临床1期IIT

Clinic Study of Ad-TD-nsIL12 Oncolytic Adenovirus in Recurrent High Grade Glioma

开始日期2023-06-28

申办/合作机构-

NCT05717699 / Recruiting临床1期IIT

Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in progressive DIPG patients (NCI-CTCAE V5.0).

开始日期2023-01-04

申办/合作机构

首都医科大学

NCT05717712 / Recruiting临床1期IIT

Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).

开始日期2023-01-04

申办/合作机构

首都医科大学

100 项与 Ad-TD-nsIL12 相关的临床结果

登录后查看更多信息

100 项与 Ad-TD-nsIL12 相关的转化医学

登录后查看更多信息

100 项与 Ad-TD-nsIL12 相关的专利（医药）

登录后查看更多信息

6

项与 Ad-TD-nsIL12 相关的文献（医药）

2024-06-01·Journal of NeuroVirology

A viral attack on brain tumors: the potential of oncolytic virus therapy

Review

作者: Mokhtarpour, Kasra ; Rezaei, Nima ; Akbarzadehmoallemkolaei, Milad

Managing malignant brain tumors remains a significant therapeutic hurdle that necessitates further research to comprehend their treatment potential fully. Oncolytic viruses (OVs) offer many opportunities for predicting and combating tumors through several mechanisms, with both preclinical and clinical studies demonstrating potential. OV therapy has emerged as a potent and effective method with a dual mechanism. Developing innovative and effective strategies for virus transduction, coupled with immune checkpoint inhibitors or chemotherapy drugs, strengthens this new technique. Furthermore, the discovery and creation of new OVs that can seamlessly integrate gene therapy strategies, such as cytotoxic, anti-angiogenic, and immunostimulatory, are promising advancements. This review presents an overview of the latest advancements in OVs transduction for brain cancer, focusing on the safety and effectiveness of G207, G47Δ, M032, rQNestin34.5v.2, C134, DNX-2401, Ad-TD-nsIL12, NSC-CRAd-S-p7, TG6002, and PVSRIPO. These are evaluated in both preclinical and clinical models of various brain tumors.

2024-01-01·Life Sciences

Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment

Article

作者: Chen, Yujia ; Li, Shenglun ; Ning, Weihai ; Zhao, Chao ; Wang, Shengdian ; Xu, Jiacheng ; Zhang, Hongwei ; Wang, Pengju ; Guo, Yuduo ; Qu, Yanming ; Wang, Yaohe ; Wang, Jun ; Zhang, Mingshan

AIMSGliomas are the most common central nervous system malignancies, with limited therapeutic options and poor prognosis, which are primarily attributed to the "immune desert" microenvironment. Previously, we constructed a three-gene-deleted oncolytic adenovirus (Ad-TD) loaded with non-secreting interleukin-12 (nsIL-12), which could be amplified in tumor cells and induce immunity to suppress tumors. However, the effects of this oncolytic virus on gliomas and their immune microenvironment remain unclear. There is an urgent need for further research.MATERIALS AND METHODSWe constructed a Syrian hamster brain tumor model and demonstrated the efficacy and mechanism of the novel oncolytic virus in treating brain tumors through a series of in vitro and in vivo experiments. We investigated the efficacy and safety (the number of hamsters in each group is either 5 or 10) of the oncolytic virus treatment in Syrian hamsters using a virus-treated group, a control virus-treated group, and a blank control group.KEY FINDINGSIn vitro assays showed that Ad-TD-nsIL-12 could specifically proliferate in brain tumor cells which induce tumor cell apoptosis and intracellular expression of interleukin (IL)-12. Moreover, in vivo experiments demonstrated that Ad-TD-nsIL-12 could effectively inhibit the progression of brain tumors and prolong survival. Ad-TD-nsIL-12 significantly enhanced T-cell infiltration in the brain tumor microenvironment.SIGNIFICANCEAd-TD-nsIL-12 can inhibit glioma progression and increase T-cell infiltration in the tumor tissue, particularly infiltration by cytotoxic T cells (CD8+). Ad-TD-nsIL-12 can amplify and produce IL-12, inducing anti-glioma immune responses to inhibit tumor progression.

2023-10-03·Expert Opinion on Biological Therapy

Oncolytic virotherapies for pediatric tumors

Review

作者: Atchley, Travis J ; Gross, Evan G ; Markert, James M ; Hamo, Mohammad A ; Laskay, Nicholas Mb ; Johnston, James M ; Estevez-Ordonez, Dagoberto

INTRODUCTIONMany pediatric patients with malignant tumors continue to suffer poor outcomes. The current standard of care includes maximum safe surgical resection followed by chemotherapy and radiation which may be associated with considerable long-term morbidity. The emergence of oncolytic virotherapy (OVT) may provide an alternative or adjuvant treatment for pediatric oncology patients.AREAS COVEREDWe reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). For each virus, we discuss the mechanism of tumor-specific replication and cytotoxicity as well as key findings of preclinical and clinical studies.EXPERT OPINIONSubstantial progress has been made in the past 10 years regarding the clinical use of OVT. From our review, OVT has favorable safety profiles compared to chemotherapy and radiation treatment. However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.

100 项与 Ad-TD-nsIL12 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫内生性脑桥神经胶质瘤	临床1期	中国	首都医科大学	2023-01-04
结直肠癌	临床前	中国	郑州大学	2017-11-09
卵巢癌	临床前	中国	郑州大学	2017-11-09
胰腺癌	临床前	中国	郑州大学	2017-11-09
胃癌	临床前	中国	郑州大学	2017-11-09